Johnson & Johnson appears better prepared for its patent cliff than Pfizer, based on their latest results. J&J's Innovative Medicine sales rose 7.8% to $16.38 billion despite a 55% decline in Stelara revenue, helped by Tremfya sales jumping 72.5% to about $2 billion. The company raised its 2026 reported-sales guidance to a midpoint of $101.1 billion and increased adjusted EPS guidance by $0.13 to $11.68. Pfizer's revenue excluding Comirnaty and Paxlovid grew 5% operationally in fiscal Q2 2026, but total operational growth was only 1%, and the company recorded a GAAP net loss of $248 million. Pfizer expects about $9.7 billion in total net savings through 2029 from cost-realignment and manufacturing-optimization programs.
Johnson & JohnsonJ&J raised 2026 sales and EPS guidance, indicating strong performance despite Stelara decline.
Pfizer IncPfizer reported a GAAP net loss and weak total growth, with only 1% operational growth overall.
